{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:01:04Z","timestamp":1779264064889,"version":"3.51.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jacadv.2025.102259","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T11:15:47Z","timestamp":1761131747000},"page":"102259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P1","title":["Statin Use in Patients With Cancer"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9862-5123","authenticated-orcid":false,"given":"Emily","family":"Chou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo S.","family":"Legasto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan K.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan H.","family":"Baik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian C.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2025.102259_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.892335","article-title":"Etiology and management of dyslipidemia in patients with cancer","volume":"9","author":"de Jesus","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"23","key":"10.1016\/j.jacadv.2025.102259_bib2","doi-asserted-by":"crossref","first-page":"9042","DOI":"10.3390\/ijms21239042","article-title":"Visceral obesity and its shared role in cancer and cardiovascular disease: a scoping review of the pathophysiology and pharmacological treatments","volume":"21","author":"Aparecida Silveira","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102259_bib3","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102259_bib4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1634\/theoncologist.2009-0285","article-title":"Obesity and cancer","volume":"15","author":"Wolin","year":"2010","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102259_bib5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2014.08.059","article-title":"A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies","volume":"66","author":"Islami","year":"2014","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102259_bib6","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1161\/CIRCULATIONAHA.112.001183","article-title":"Ideal cardiovascular health is inversely associated with incident cancer: the atherosclerosis risk in communities study","volume":"127","author":"Rasmussen-Torvik","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102259_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/hsz-2014-0194","article-title":"Cholesterol lowering: role in cancer prevention and treatment","volume":"396","author":"Murai","year":"2015","journal-title":"Biol Chem"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102259_bib8","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1042\/bj0251991","article-title":"The phosphatide and cholesterol contents of normal and malignant human tissues","volume":"25","author":"Jowett","year":"1931","journal-title":"Biochem J"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102259_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/annonc\/mdr155","article-title":"Dietary cholesterol intake and cancer","volume":"23","author":"Hu","year":"2012","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102259_bib10","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1158\/2159-8290.CD-21-0211","article-title":"Cholesterol auxotrophy as a targetable vulnerability in clear cell renal cell carcinoma","volume":"11","author":"Riscal","year":"2021","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.jacadv.2025.102259_bib11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/CIRCULATIONAHA.120.046471","article-title":"Early cardiac remodeling promotes tumor growth and metastasis","volume":"142","author":"Avraham","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102259_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamainternmed.2020.6084","article-title":"Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis","volume":"181","author":"Yourman","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102259_bib13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamainternmed.2015.0289","article-title":"Safety and benefit of discontinuing Statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial","volume":"175","author":"Kutner","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102259_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.13186","article-title":"Cardiovascular outcomes and mortality associated with discontinuing statins in older patients receiving polypharmacy","volume":"4","author":"Rea","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102259_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-000880","article-title":"Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage","volume":"2","author":"Stavrou","year":"2012","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102259_bib16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/jpm.2007.0215","article-title":"Statins in the last six months of life: a recognizable, life-limiting condition does not decrease their use","volume":"11","author":"Silveira","year":"2008","journal-title":"J Palliat Med"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102259_bib17","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/annonc\/mdv029","article-title":"Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions","volume":"26","author":"van Leeuwen","year":"2015","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.jacadv.2025.102259_bib18","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American heart association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102259_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105119","article-title":"Clinical relevance and methodological approach for the assessment of drug-drug interactions in cancer patients: a position statement from the Italian association of medical oncology (AIOM) and the Italian society of pharmacology (SIF)","volume":"10","author":"Del Re","year":"2025","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102259_bib21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jsps.2023.04.002","article-title":"Statins utilization trends and expenditures in the U.S. before and after the implementation of the 2013 ACC\/AHA guidelines","volume":"31","author":"Matyori","year":"2023","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.jacadv.2025.102259_bib24","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jacadv.2025.102259_bib25","series-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses","author":"Wells","year":"2000"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102259_bib26","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.thromres.2014.09.001","article-title":"Statins are associated with low risk of venous thromboembolism in patients with cancer: a prospective and observational cohort study","volume":"134","author":"L\u00f6tsch","year":"2014","journal-title":"Thromb Res"},{"issue":"10","key":"10.1016\/j.jacadv.2025.102259_bib27","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1158\/1055-9965.EPI-15-0671","article-title":"Postdiagnostic statin use and the risk of lethal prostate cancer in the health professionals Follow-up study","volume":"24","author":"Chan","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"42","key":"10.1016\/j.jacadv.2025.102259_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001801","article-title":"Statin-based palliative therapy for hepatocellular carcinoma","volume":"94","author":"Shao","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"17","key":"10.1016\/j.jacadv.2025.102259_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003392","article-title":"Statins are associated with a reduced risk of brain cancer: a population-based case-control study","volume":"95","author":"Chen","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102259_bib30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/bjc.2015.376","article-title":"Relation of statin use with non-melanoma skin cancer: prospective results from the Women\u2019s health initiative","volume":"114","author":"Wang","year":"2016","journal-title":"Br J Cancer"},{"issue":"36","key":"10.1016\/j.jacadv.2025.102259_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004639","article-title":"Statins improve outcomes of nonsurgical curative treatments in hepatocellular carcinoma patients","volume":"95","author":"Wu","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102259_bib32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/21681805.2017.1362032","article-title":"Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy","volume":"51","author":"Mikkelsen","year":"2017","journal-title":"Scand J Urol"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102259_bib33","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.21873\/anticanres.11469","article-title":"Statins protect against acute RT-related rectal toxicity in patients with prostate cancer: an observational prospective study","volume":"37","author":"Palumbo","year":"2017","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102259_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jamaoncol.2017.2752","article-title":"Examining bias in studies of statin treatment and survival in patients with cancer","volume":"4","author":"Emilsson","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102259_bib35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.urolonc.2018.11.017","article-title":"The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: a large observational study","volume":"37","author":"Anderson-Carter","year":"2019","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102259_bib36","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.21873\/anticanres.13332","article-title":"Association of statin use and oncological outcomes after neoadjuvant radiotherapy in patients with rectal cancer","volume":"39","author":"Fransgaard","year":"2019","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102259_bib37","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1210\/clinem\/dgaa877","article-title":"Clinical, cellular, and molecular evidence of the additive antitumor effects of biguanides and statins in prostate cancer","volume":"106","author":"Jim\u00e9nez-Vacas","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.jacadv.2025.102259_bib38","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/ijc.33333","article-title":"Statin use and survival following a diagnosis of ovarian cancer: a prospective observational study","volume":"148","author":"Majidi","year":"2021","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102259_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142616","article-title":"Atorvastatin is associated with reduced cisplatin-induced hearing loss","volume":"131","author":"Fernandez","year":"2021","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102259_bib40","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s11606-020-06167-5","article-title":"Association between statins and cancer incidence in diabetes: a cohort study of Japanese patients with type 2 diabetes","volume":"36","author":"Okada","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102259_bib41","article-title":"Statins and immunotherapy: togetherness makes strength the potential effect of statins on immunotherapy for NSCLC","volume":"4","author":"Rossi","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102259_bib42","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12876-022-02505-5","article-title":"Association between metabolic syndrome and colorectal cancer incidence and all-cause mortality: a hospital-based observational study","volume":"22","author":"Chung","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102259_bib43","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.surg.2021.08.002","article-title":"Statin therapy and its association with long-term survival after Colon cancer surgery","volume":"171","author":"Pourlotfi","year":"2022","journal-title":"Surgery"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102259_bib44","first-page":"660","article-title":"Does Statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study","volume":"31","author":"Okamoto","year":"2023","journal-title":"Support Care Cancer"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102259_bib45","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1158\/0008-5472.CAN-23-2941","article-title":"Regular use of aspirin and statins reduces the risk of cancer in individuals with systemic inflammatory diseases","volume":"84","author":"Lin","year":"2024","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102259_bib46","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102259_bib47","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/oncolo\/oyad051","article-title":"Practical guidance for the management of adverse events in patients with KRASG12C-Mutated non-small cell lung cancer receiving adagrasib","volume":"28","author":"Zhang","year":"2023","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102259_bib48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102259_bib49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem Sci"},{"issue":"24","key":"10.1016\/j.jacadv.2025.102259_bib50","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102259_bib51","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3138\/ptc.2012-65","article-title":"Statin-induced rhabdomyolysis: a comprehensive review of case reports","volume":"66","author":"Mendes","year":"2014","journal-title":"Physiother Can"},{"key":"10.1016\/j.jacadv.2025.102259_bib52","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/1750743X.2024.2427563","article-title":"Fatal rhabdomyolysis and fulminant myocarditis with malignant arrhythmias after one dose of ipilimumab and nivolumab","volume":"16","author":"Kurnik","year":"2024","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102259_bib53","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102259_bib54","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cjco.2022.08.006","article-title":"Statins protect against early stages of doxorubicin-induced cardiotoxicity through the regulation of Akt signaling and SERCA2","volume":"4","author":"Dadson","year":"2022","journal-title":"CJC Open"},{"issue":"7","key":"10.1016\/j.jacadv.2025.102259_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007307","article-title":"Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer","volume":"11","author":"Drobni","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.jacadv.2025.102259_bib56","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jacadv.2025.102259_bib57","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jacadv.2025.102259_bib58","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jacadv.2025.102259_bib59","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102259_bib60","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2010.03942.x","article-title":"Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy","volume":"74","author":"Hamilton","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102259_bib61","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.ijir.3901471","article-title":"Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy","volume":"18","author":"Braga-Basaria","year":"2006","journal-title":"Int J Impot Res"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102259_bib62","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy","volume":"106","author":"Basaria","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102259_bib63","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102259_bib64","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102259_bib65","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jtho.2023.09.004","article-title":"Bidirectional association between cardiovascular disease and lung cancer in a prospective cohort study","volume":"19","author":"Zhang","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102259_bib66","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1289\/ehp.1103639","article-title":"Lung cancer and cardiovascular disease mortality associated with ambient air pollution and cigarette smoke: shape of the exposure-response relationships","volume":"119","author":"Pope","year":"2011","journal-title":"Environ Health Perspect"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102259_bib67","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/ije\/dyaa128","article-title":"Cancer cure for 32 cancer types: results from the EUROCARE-5 study","volume":"49","author":"Dal Maso","year":"2020","journal-title":"Int J Epidemiol"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X2500688X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X2500688X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:25:21Z","timestamp":1775067921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X2500688X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2772963X2500688X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102259","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin Use in Patients With Cancer","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102259"}}